Format

Send to

Choose Destination
Pharmacol Res. 2019 Mar;141:343-356. doi: 10.1016/j.phrs.2019.01.020. Epub 2019 Jan 11.

Current evidence and future perspectives for curcumin and its analogues as promising adjuncts to oxaliplatin: state-of-the-art.

Author information

1
School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
2
Weill Cornell Medicine Qatar, Doha, Qatar.
3
Sabinsa Corporation, East Windsor, NJ, United States.
4
Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: sahebkara@mums.ac.ir.

Abstract

Curcumin is a multifunctional phytochemical that has documented anti-oxidant, anti-inflammatory and anti-tumor properties. The anti-tumor effect of curcumin has been widely investigated, both as a single ingredient and in combination with chemotherapeutic agents. Oxaliplatin is a third-generation platinum agent with established effectiveness in multiple malignancies including gastroesophageal, colorectal, pancreas, ovarian, breast and head and neck cancers. The effects of curcumin and its synthetic analogues in combination with oxaliplatin have been studied in a variety of malignant cell lines in vitro and in vivo, providing evidence supporting the beneficial effects of curcumin as an adjunct to oxaliplatin, though dose, combination ratio and the timing of exposure to the agents are covariates that may affect the therapeutic efficacy and need to be determined. This review provides a summary of the studies investigating the effects of curcumin and its analogues, as adjuvants to oxaliplatin treatment in malignant cell lines and experimental tumor models. Addition of curcumin as an adjunct to oxaliplatin enhances oxaliplatin's toxicity in malignant cells, which potentially allows an oxaliplatin dose reduction and decreasing the adverse effects of chemotherapy. Curcumin has also been studied in several nonmalignant cell types and has been shown to exert cytoprotective properties against oxaliplatin's off-target toxicities. Despite all of the promising evidence to date, there is a scarcity of supportive evidence from clinical trials on the adjuvant use of curcumin, which needs future translational and clinical studies.

KEYWORDS:

Adjuvant; Chemotherapy; Curcumin; Oxaliplatin

PMID:
30641277
DOI:
10.1016/j.phrs.2019.01.020

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center